Organogenesis Holdings Inc Asset Resilience Ratio
Organogenesis Holdings Inc asset resilience ratio. Organogenesis Holdings Inc (ORGO) has an Asset Resilience Ratio of 0.26% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Organogenesis Holdings Inc (ORGO) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Organogenesis Holdings Inc (2001–2016)
Asset resilience ratio of Organogenesis Holdings Inc from 2001 to 2016. This chart shows how Organogenesis Holdings Inc's Asset Resilience Ratio has changed over time. See ORGO free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Organogenesis Holdings Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ORGO asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.16 Million | 0.26% |
| Total Liquid Assets | $1.16 Million | 0.26% |
Asset Resilience Insights
- Limited Liquidity: Organogenesis Holdings Inc maintains only 0.26% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Organogenesis Holdings Inc Industry Peers by Asset Resilience Ratio
Compare Organogenesis Holdings Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Ahn-Gook Pharmaceutical Co. Ltd
KQ:001540 |
Drug Manufacturers - Specialty & Generic | 3.23% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE |
Drug Manufacturers - Specialty & Generic | 1.38% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 29.37% |
|
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
SHG:688505 |
Drug Manufacturers - Specialty & Generic | 11.06% |
|
HPGC Renmintongtai Pharmaceutical Corp
SHG:600829 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Organogenesis Holdings Inc Asset Resilience Ratio by Year (2001–2016)
Organogenesis Holdings Inc asset resilience ratio by year from 2001 to 2016. The table below shows the annual Asset Resilience Ratio data for Organogenesis Holdings Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2016-12-31 | 0.05% | $151.00K | $311.44 Million | -4.34pp |
| 2001-12-31 | 4.38% | $114.80K | $2.62 Million | -- |
About Organogenesis Holdings Inc
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barrier… Read more